Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Biocon unit plans 15% stake sale to Serum Institute for access to vaccines

Stock MarketsSep 17, 2021 06:07AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines, which is working on vaccines against the coronavirus disease (COVID-19) in Pune, India, May 18, 2020. REUTERS/Euan Rocha/File Pho

By Shivani Singh

BENGALURU (Reuters) -Biocon Ltd said late on Thursday its biologics unit will sell a 15% stake to a Serum Institute of India (SII) subsidiary for access to 100 million doses of vaccines annually for 15 years, including COVID-19 shots.

SII, which makes AstraZeneca (NASDAQ:AZN)'s COVID-19 shot, branded as Covishield in India, is the world's largest vaccine maker.

The deal with Serum Institute Life Sciences values Biocon Biologics at about $4.9 billion and will solely focus on COVID-19 vaccines in the initial years, the companies said.

The 15% stake in the Biocon unit is valued at more than $730 million, Biocon's Executive Chairperson Kiran Mazumdar-Shaw said.

The unit, which makes pharmaceutical ingredients, will gain a foothold in the vaccine manufacturing space following the deal.

As part of the deal, the Biocon unit and the SII subsidiary will make and distribute vaccines and antibody treatments.

Biocon Biologics will also invest in setting up a research division for vaccines, with SII Chief Executive Officer Adar Poonawalla getting a seat on the board of the Biocon unit.

SII also expects to ramp up its Covishield manufacturing capacity to 200 million doses per month, Poonawalla said at a media briefing on Friday.

While there is a current ban on COVID-19 vaccine exports in India, Poonawalla said SII was trying to strengthen its supply chain and source raw materials from within the country as well.

SII is also manufacturing and stockpiling Novavax (NASDAQ:NVAX) Inc's COVID-19 vaccine, which is yet to be granted approval by the Indian health authorities.

In January, Abu Dhabi-based investment firm ADQ invested $75.47 million in Biocon Biologics for a 1.8% stake.

Biocon Ltd's shares rose as much as 4.6% early on Friday but gave up gains to trade 0.67% lower amid losses in the broader market. (BO)

($1 = 73.5350 Indian rupees)

Biocon unit plans 15% stake sale to Serum Institute for access to vaccines
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email